Insider Cluster (2 insiders) ·Filed Jul 8, 2026

PALI

PALISADE BIO, INC.
NEUTRAL
Impact 3/10
Horizondays Processed2mo ago
Insider cluster: 2 insiders, $323K total
Actionable Insight • Neutral

The insider activity is too small to warrant a directional trade. Monitor the next earnings release or any material corporate events—the CEO's sale may be liquidity-driven (e.g., tax planning or diversification). No immediate read-through for PALI shares.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+20d
PALI ▲ +6.09% at T+20d
NEUTRAL call ✓ call won +6.09% · α vs SPY +3.85% · entry $1.97 → $2.09
Next anchor: T+60d due yesterday
Latest observation: T+59 -39.84% FF3 residual α
Entry anchored
Jul 8, 03:59 PM ET
via exchange tick
T+1d
-0.51%
call -0.51% · α -0.94%
$1.96
settled 3mo ago
T+5d
-4.06%
call -4.06% · α -3.93%
$1.89
settled 3mo ago
T+20d
+6.09%
call +6.09% · α +3.85%
$2.09
settled 8w ago
T+60d
—
call — · α —
—
due yesterday

Price Chart

Loading chart...

Executive Summary

Insider trading cluster at PALISADE BIO shows CEO/CFO John David Finley selling $303K in open-market shares, while Director Robert Baltera Jr. bought $20K. The total value of the cluster ($323K) represents only ~0.09% of the company's $361M market cap, making the activity trivial in scale. The CEO sale is a single open-market transaction, not a cluster of multiple executives, and per academic literature insider sales are weak predictors of forward returns, especially at this magnitude.

Key Financial Metrics

Direction
mixed
Total Value
$323.1K
Insiders
2

Key Facts

  • CEO/CFO Finley sold 146,798 shares at $2.07 for $303,343 on 2026-07-07
  • Director Baltera bought 10,000 shares at $1.98 for $19,800 on 2026-07-02
  • Total cluster value of $323K is ~0.09% of $361M market cap
  • Derivative exercises by CEO on 2026-07-06 and 2026-07-07 were non-cash events (zero value)

Financial Impact

Net insider selling of $283K (buy minus sell) is trivial relative to $361M market cap

Risk Factors

  • CEO selling could be misinterpreted as negative by the market despite small size
  • No material insider buying to offset the sell, reducing confidence in near-term upside

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-PALI-1783550999740
8 reports for PALI
Performance horizon
Filters
Rows
Reports for PALI — sortable, filterable
TypeNow
Aug 10, 2026
7w ago
8-K
NEUTRAL ★ 5/10
$2.14 $2.05▼ −4.21%▼ −3.15%$1.45 (−32.48%)
Jul 10, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$1.89 $2.10▲ +11.11%▲ +7.93%$1.45 (−23.54%)
Jul 8, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$1.97 $2.09▲ +6.09%▲ +3.85%$1.45 (−26.65%)
Jun 11, 2026
16w ago
8-K
NEUTRAL ★ 4/10
$1.71 $1.96▲ +14.62%▲ +12.84%$1.45 (−15.50%)
May 22, 2026
19w ago
EFFECT
NEUTRAL ★ 4/10
$1.95 $1.89▼ −3.08%▼ −1.66%$1.45 (−25.90%)
May 12, 2026
20w ago
S-3
NEUTRAL ★ 5/10
$1.87 $1.78▼ −4.81%▼ −4.20%$1.45 (−22.73%)
Apr 29, 2026
22w ago
DEFA14A
NEUTRAL ★ 2/10
$2.00 $2.12▲ +6.00%▲ +0.77%$1.45 (−27.75%)
Apr 2, 2026
26w ago
8-K
NEUTRAL ★ 5/10
$1.89 $2.00▲ +5.82%▼ −4.06%$1.45 (−23.54%)
Showing 8 of 8

US Market Status

Market Open — Closes in 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 8, 2026